Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM)
Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome. To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes. Double-blind, randomise...
Uloženo v:
| Vydáno v: | Health technology assessment (Winchester, England) Ročník 22; číslo 35; s. 1 - 304 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
NIHR Journals Library
01.06.2018
|
| Témata: | |
| ISSN: | 1366-5278, 2046-4924, 2046-4924 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.
To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes.
Double-blind, randomised placebo-controlled trial.
Obstetric units in the UK and Europe between February 2009 and April 2013.
Women with a singleton pregnancy who are at high risk of preterm birth because of either a positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks
of gestation or a cervical length of ≤ 25 mm.
Fibronectin test at 18
to 23
weeks of pregnancy to determine risk of preterm birth. Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or placebo, taken vaginally daily from 22
to 24
until 34
weeks' gestation. Participants, caregivers and those assessing the outcomes were blinded to group assignment until data collection was complete.
There were three primary outcomes, as follows: (1) obstetric - fetal death or delivery before 34
weeks' gestation; (2) neonatal - a composite of death, brain injury on ultrasound scan (according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood - the Bayley-III cognitive composite score at 22-26 months of age.
In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval (CI) 0.61 to 1.22]. Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of
women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17]. The mean Bayley-III cognitive composite score of the children at 2 years of age was 97.3 points [standard deviation (SD) 17.9 points;
= 430] in the progesterone group and 97.7 points (SD 17.5 points;
= 439) in the placebo group (difference in means -0.48, 95% CI -2.77 to 1.81).
Overall compliance with the intervention was 69%.
There were no major harms, although there was a trend of more deaths from trial entry to 2 years in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42).
In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate in a comprehensive individual patient-level data meta-analysis examining women with a singleton pregnancy with a variety of risk factors for preterm birth.
Current Controlled Trials ISRCTN14568373.
This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. |
|---|---|
| AbstractList | Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.
To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes.
Double-blind, randomised placebo-controlled trial.
Obstetric units in the UK and Europe between February 2009 and April 2013.
Women with a singleton pregnancy who are at high risk of preterm birth because of either a positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks
of gestation or a cervical length of ≤ 25 mm.
Fibronectin test at 18
to 23
weeks of pregnancy to determine risk of preterm birth. Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or placebo, taken vaginally daily from 22
to 24
until 34
weeks' gestation. Participants, caregivers and those assessing the outcomes were blinded to group assignment until data collection was complete.
There were three primary outcomes, as follows: (1) obstetric - fetal death or delivery before 34
weeks' gestation; (2) neonatal - a composite of death, brain injury on ultrasound scan (according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood - the Bayley-III cognitive composite score at 22-26 months of age.
In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval (CI) 0.61 to 1.22]. Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of
women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17]. The mean Bayley-III cognitive composite score of the children at 2 years of age was 97.3 points [standard deviation (SD) 17.9 points;
= 430] in the progesterone group and 97.7 points (SD 17.5 points;
= 439) in the placebo group (difference in means -0.48, 95% CI -2.77 to 1.81).
Overall compliance with the intervention was 69%.
There were no major harms, although there was a trend of more deaths from trial entry to 2 years in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42).
In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate in a comprehensive individual patient-level data meta-analysis examining women with a singleton pregnancy with a variety of risk factors for preterm birth.
Current Controlled Trials ISRCTN14568373.
This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Background: Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome. Objective: To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes. Design: Double-blind, randomised placebo-controlled trial. Setting: Obstetric units in the UK and Europe between February 2009 and April 2013. Participants: Women with a singleton pregnancy who are at high risk of preterm birth because of either a positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks+0 of gestation or a cervical length of ≤ 25 mm. Interventions: Fibronectin test at 18+0 to 23+0 weeks of pregnancy to determine risk of preterm birth. Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or placebo, taken vaginally daily from 22+0 to 24+0 until 34+0 weeks’ gestation. Participants, caregivers and those assessing the outcomes were blinded to group assignment until data collection was complete. Main outcome measures: There were three primary outcomes, as follows: (1) obstetric – fetal death or delivery before 34+0 weeks’ gestation; (2) neonatal – a composite of death, brain injury on ultrasound scan (according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood – the Bayley-III cognitive composite score at 22–26 months of age. Results: In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval (CI) 0.61 to 1.22]. Thirty-nine out of 589 (7%) babies of women in the progesterone group and 60 out of 587 (10%) babies of women in the placebo group experienced the primary neonatal outcome [OR 0.62, 95% CI 0.38 to 1.03]. The mean Bayley-III cognitive composite score of the children at 2 years of age was 97.3 points [standard deviation (SD) 17.9 points; n = 430] in the progesterone group and 97.7 points (SD 17.5 points; n = 439) in the placebo group (difference in means –0.48, 95% CI –2.77 to 1.81). Limitations: Overall compliance with the intervention was 69%. Harms: There were no major harms, although there was a trend of more deaths from trial entry to 2 years in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42). Conclusions: In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate in a comprehensive individual patient-level data meta-analysis examining women with a singleton pregnancy with a variety of risk factors for preterm birth. Trial registration: Current Controlled Trials ISRCTN14568373. Funding: This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC–NIHR partnership. Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.BACKGROUNDProgesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes.OBJECTIVETo determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes.Double-blind, randomised placebo-controlled trial.DESIGNDouble-blind, randomised placebo-controlled trial.Obstetric units in the UK and Europe between February 2009 and April 2013.SETTINGObstetric units in the UK and Europe between February 2009 and April 2013.Women with a singleton pregnancy who are at high risk of preterm birth because of either a positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks+0 of gestation or a cervical length of ≤ 25 mm.PARTICIPANTSWomen with a singleton pregnancy who are at high risk of preterm birth because of either a positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks+0 of gestation or a cervical length of ≤ 25 mm.Fibronectin test at 18+0 to 23+0 weeks of pregnancy to determine risk of preterm birth. Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or placebo, taken vaginally daily from 22+0 to 24+0 until 34+0 weeks' gestation. Participants, caregivers and those assessing the outcomes were blinded to group assignment until data collection was complete.INTERVENTIONSFibronectin test at 18+0 to 23+0 weeks of pregnancy to determine risk of preterm birth. Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or placebo, taken vaginally daily from 22+0 to 24+0 until 34+0 weeks' gestation. Participants, caregivers and those assessing the outcomes were blinded to group assignment until data collection was complete.There were three primary outcomes, as follows: (1) obstetric - fetal death or delivery before 34+0 weeks' gestation; (2) neonatal - a composite of death, brain injury on ultrasound scan (according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood - the Bayley-III cognitive composite score at 22-26 months of age.MAIN OUTCOME MEASURESThere were three primary outcomes, as follows: (1) obstetric - fetal death or delivery before 34+0 weeks' gestation; (2) neonatal - a composite of death, brain injury on ultrasound scan (according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood - the Bayley-III cognitive composite score at 22-26 months of age.In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval (CI) 0.61 to 1.22]. Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17]. The mean Bayley-III cognitive composite score of the children at 2 years of age was 97.3 points [standard deviation (SD) 17.9 points; n = 430] in the progesterone group and 97.7 points (SD 17.5 points; n = 439) in the placebo group (difference in means -0.48, 95% CI -2.77 to 1.81).RESULTSIn total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval (CI) 0.61 to 1.22]. Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17]. The mean Bayley-III cognitive composite score of the children at 2 years of age was 97.3 points [standard deviation (SD) 17.9 points; n = 430] in the progesterone group and 97.7 points (SD 17.5 points; n = 439) in the placebo group (difference in means -0.48, 95% CI -2.77 to 1.81).Overall compliance with the intervention was 69%.LIMITATIONSOverall compliance with the intervention was 69%.There were no major harms, although there was a trend of more deaths from trial entry to 2 years in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42).HARMSThere were no major harms, although there was a trend of more deaths from trial entry to 2 years in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42).In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate in a comprehensive individual patient-level data meta-analysis examining women with a singleton pregnancy with a variety of risk factors for preterm birth.CONCLUSIONSIn this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate in a comprehensive individual patient-level data meta-analysis examining women with a singleton pregnancy with a variety of risk factors for preterm birth.Current Controlled Trials ISRCTN14568373.TRIAL REGISTRATIONCurrent Controlled Trials ISRCTN14568373.This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership.FUNDINGThis trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. |
| Author | Messow, Claudia-Martina Lavender, Tina Thornton, Steven Petrou, Stavros Marlow, Neil Bennett, Philip R McConnachie, Alex Norman, Jane E Sebire, Neil J Whyte, Sonia Robson, Stephen C Shennan, Andrew Norrie, John |
| Author_xml | – sequence: 1 givenname: Jane E orcidid: 0000-0001-6031-6953 surname: Norman fullname: Norman, Jane E organization: Tommy’s Centre for Maternal and Fetal Health, MRC Centre for Maternal and Fetal Health, University of Edinburgh, Edinburgh, UK – sequence: 2 givenname: Neil surname: Marlow fullname: Marlow, Neil organization: Institute of Women’s Health, University College London, London, UK – sequence: 3 givenname: Claudia-Martina orcidid: 0000-0003-0082-9946 surname: Messow fullname: Messow, Claudia-Martina organization: Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK – sequence: 4 givenname: Andrew orcidid: 0000-0001-5273-3132 surname: Shennan fullname: Shennan, Andrew organization: Women’s Health Academic Centre, King’s College London, London, UK – sequence: 5 givenname: Philip R orcidid: 0000-0002-6253-4919 surname: Bennett fullname: Bennett, Philip R organization: Obstetrics and Gynaecology, Department of Surgery and Cancer, Imperial College London, London, UK – sequence: 6 givenname: Steven orcidid: 0000-0001-7613-0408 surname: Thornton fullname: Thornton, Steven organization: Obstetrics and Gynaecology (Barts), Queen Mary University of London, London, UK – sequence: 7 givenname: Stephen C orcidid: 0000-0001-7897-7987 surname: Robson fullname: Robson, Stephen C organization: The Medical School, University of Newcastle, Newcastle, UK – sequence: 8 givenname: Alex orcidid: 0000-0002-7262-7000 surname: McConnachie fullname: McConnachie, Alex organization: Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK – sequence: 9 givenname: Stavros orcidid: 0000-0003-3121-6050 surname: Petrou fullname: Petrou, Stavros organization: Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK – sequence: 10 givenname: Neil J orcidid: 0000-0001-5348-9063 surname: Sebire fullname: Sebire, Neil J organization: Institute of Women’s Health, University College London, London, UK – sequence: 11 givenname: Tina orcidid: 0000-0003-1473-4956 surname: Lavender fullname: Lavender, Tina organization: School of Nursing, University of Manchester, Manchester, UK – sequence: 12 givenname: Sonia orcidid: 0000-0003-0878-4244 surname: Whyte fullname: Whyte, Sonia organization: Tommy’s Centre for Maternal and Fetal Health, MRC Centre for Maternal and Fetal Health, University of Edinburgh, Edinburgh, UK – sequence: 13 givenname: John orcidid: 0000-0001-9823-9252 surname: Norrie fullname: Norrie, John organization: Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, Aberdeen, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29945711$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkstu1TAQhi1URE8LEk-AsmwXKb7H3oCqcjtSq3bRri3HmZzjyomDkxzRF-C5cegFCqvRzPzzjfTPHKC9PvaA0FuCTxgj-P12spQygV-gFcVcllxTvodWhElZClqpfXQwjrcYcyIFeYX2qdZcVISs0M9PEcZiSHED4wQpY5dk2N4F-8OPxRRzCjvopyVmQVcEW8c5Fb7Luh0UcZ5c7OBjcVok2zex8yM0RRPnOkBZB983xRCsgzqWLvZTiiHk_pS8DcXR5dXV9fri5uL4NXrZ2jDCm4d4iG6-fL4--1aeX35dn52el45VGpc1rSRvlJWWWiBUy0ooBQ2o1omKAQVNXS1F6xwnpK04y-60lErpsLKEE3aI1vfcJtpbMyTf2XRnovXmdyGmjbFp8i6AwULrqmGNIy3nWEoFSguuNKPAJakW1od71jDXHTQum5RseAZ93un91mzizkjMJMciA44eACl-n7P_JpvnIATbQ5xHQ7HESmoseJa--3vX05LHQ_5huRTHMUH7JCHYLD9iHn8kS0_-kTo_2ckv17E-_D_wC1V0vwU |
| CitedBy_id | crossref_primary_10_1016_j_placenta_2019_01_018 crossref_primary_10_1080_14767058_2021_1943657 crossref_primary_10_1038_s41390_018_0180_z crossref_primary_10_1055_a_1741_6172 crossref_primary_10_1016_j_placenta_2019_03_010 crossref_primary_10_1016_j_placenta_2020_07_021 crossref_primary_10_1055_a_1877_5827 crossref_primary_10_3389_fimmu_2019_03156 crossref_primary_10_1038_s44321_025_00211_9 crossref_primary_10_1152_physrev_00019_2023 crossref_primary_10_2147_JIR_S495132 crossref_primary_10_3389_fmed_2023_1111315 crossref_primary_10_1007_s43032_022_00926_x crossref_primary_10_1177_01939459211030339 crossref_primary_10_1038_s41598_021_99185_0 crossref_primary_10_1186_s12884_022_04711_1 crossref_primary_10_1186_s12884_025_07488_1 crossref_primary_10_1111_1471_0528_16582 |
| Cites_doi | 10.1016/S0140-6736(00)04234-3 10.1016/S0140-6736(08)61203-9 10.1056/NEJM200005183422007 10.1056/NEJMoa035140 10.1056/NEJMoa067815 10.1002/uog.9017 10.1016/S0140-6736(00)04337-3 10.1002/14651858.CD004947.pub3 10.1186/1471-2393-12-79 10.1016/S0140-6736(16)00350-0 10.1002/mrdd.10003 10.1097/01.AOG.0000150559.59531.b2 10.1026//0942-5403.8.1.23 10.1038/pr.2013.204 10.1016/j.ajog.2011.12.003 10.1067/mob.2003.41 10.1016/j.ajog.2012.03.010 10.1111/j.1471-0528.2004.00420.x |
| ContentType | Journal Article |
| CorporateAuthor | for the OPPTIMUM study group |
| CorporateAuthor_xml | – name: for the OPPTIMUM study group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3310/hta22350 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2046-4924 |
| EndPage | 304 |
| ExternalDocumentID | oai_doaj_org_article_05997d3dc1f440668e89548932e46171 PMC6036405 29945711 10_3310_hta22350 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GrantInformation | This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. |
| GrantInformation_xml | – fundername: Chief Scientist Office grantid: HSRU1 – fundername: Medical Research Council grantid: G0501681 |
| GroupedDBID | --- 53G 5GY AAYXX ADBBV ADDVE AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CITATION CZQ DIK EBS EJD F5P GROUPED_DOAJ OK1 P2P P6G TR2 W2D CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c3790-b2764d8a6a2ae12967588ede8fc573e2e92cb65fcc411f743331f2266c08a1413 |
| IEDL.DBID | DOA |
| ISSN | 1366-5278 2046-4924 |
| IngestDate | Fri Oct 03 12:53:37 EDT 2025 Thu Aug 21 14:06:35 EDT 2025 Fri Jul 11 11:14:25 EDT 2025 Sat May 31 02:08:50 EDT 2025 Sat Nov 29 03:04:24 EST 2025 Tue Nov 18 22:33:34 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 35 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3790-b2764d8a6a2ae12967588ede8fc573e2e92cb65fcc411f743331f2266c08a1413 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-3121-6050 0000-0002-6253-4919 0000-0001-7897-7987 0000-0003-0082-9946 0000-0003-0878-4244 0000-0003-1473-4956 0000-0001-7613-0408 0000-0001-6031-6953 0000-0001-5348-9063 0000-0002-7262-7000 0000-0001-9823-9252 0000-0001-5273-3132 |
| OpenAccessLink | https://doaj.org/article/05997d3dc1f440668e89548932e46171 |
| PMID | 29945711 |
| PQID | 2060869054 |
| PQPubID | 23479 |
| PageCount | 304 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_05997d3dc1f440668e89548932e46171 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6036405 proquest_miscellaneous_2060869054 pubmed_primary_29945711 crossref_primary_10_3310_hta22350 crossref_citationtrail_10_3310_hta22350 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-01 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Health technology assessment (Winchester, England) |
| PublicationTitleAlternate | Health Technol Assess |
| PublicationYear | 2018 |
| Publisher | NIHR Journals Library |
| Publisher_xml | – name: NIHR Journals Library |
| References | da Fonseca (key2019021912542515_ref1-bib2) 2003; 188 Blencowe (key2019021912542515_ref1-bib5) 2013; 74 National Institutes of Health U.S (key2019021912542515_ref1-bib10) 2017 Wolke (key2019021912542515_ref1-bib24) 1999; 8 Kenyon (key2019021912542515_ref1-bib16) 2008; 372 Dodd (key2019021912542515_ref1-bib6) 2013; 7 Kenyon (key2019021912542515_ref1-bib15) 2001; 357 Hassan (key2019021912542515_ref1-bib11) 2011; 38 Medscape (key2019021912542515_ref1-bib12) Moher (key2019021912542515_ref1-bib19) 2001; 357 Meis (key2019021912542515_ref1-bib1) 2002; 187 Romero (key2019021912542515_ref1-bib7) 2012; 206 Sanchez-Ramos (key2019021912542515_ref1-bib23) 2005; 105 Norman (key2019021912542515_ref1-bib17) 2012; 12 Meis (key2019021912542515_ref1-bib9) 2003; 348 Shennan (key2019021912542515_ref1-bib22) 2005; 112 Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella (key2019021912542515_ref1-bib20) 2012; 206 Childstats.gov (key2019021912542515_ref1-bib4) Office for National Statistics (key2019021912542515_ref1-bib3) Fonseca (key2019021912542515_ref1-bib18) 2007; 357 Goldenberg (key2019021912542515_ref1-bib13) 2000; 342 Wu (key2019021912542515_ref1-bib14) 2002; 8 National Institute for Health and Care Excellence (NICE) (key2019021912542515_ref1-bib21) 2015 Norman (key2019021912542515_ref1-bib8) 2016; 387 |
| References_xml | – volume: 357 start-page: 989 year: 2001 ident: key2019021912542515_ref1-bib15 article-title: Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group publication-title: Lancet doi: 10.1016/S0140-6736(00)04234-3 – volume: 187 start-page: S54 year: 2002 ident: key2019021912542515_ref1-bib1 article-title: 17 alpha hydroxyprogesterone actetate to prevent recurrent preterm birth publication-title: Am J Obstet Gynaecol – volume: 372 start-page: 1319 year: 2008 ident: key2019021912542515_ref1-bib16 article-title: Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial publication-title: Lancet doi: 10.1016/S0140-6736(08)61203-9 – volume-title: MAKENA year: 2017 ident: key2019021912542515_ref1-bib10 article-title: National Library of Medicine – volume: 342 start-page: 1500 year: 2000 ident: key2019021912542515_ref1-bib13 article-title: Intrauterine infection and preterm delivery publication-title: N Engl J Med doi: 10.1056/NEJM200005183422007 – volume-title: Live Births and Stillbirths by Gestation, Birthweight, Multiplicity and Region. Infant Deaths by Gestation, Birthweight, Multiplicity, Region and Cause Group, England, 2015 ident: key2019021912542515_ref1-bib3 – volume: 348 start-page: 2379 year: 2003 ident: key2019021912542515_ref1-bib9 article-title: Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate publication-title: N Engl J Med doi: 10.1056/NEJMoa035140 – volume: 357 start-page: 462 year: 2007 ident: key2019021912542515_ref1-bib18 article-title: Progesterone and the risk of preterm birth among women with a short cervix publication-title: N Engl J Med doi: 10.1056/NEJMoa067815 – volume-title: America’s Children: Key National Indicators of Well-being, 2017 ident: key2019021912542515_ref1-bib4 – volume-title: FDA Panel Votes Down 8% Progesterone Gel for Preterm Births ident: key2019021912542515_ref1-bib12 – volume: 38 start-page: 18 year: 2011 ident: key2019021912542515_ref1-bib11 article-title: Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial publication-title: Ultrasound Obstet Gynecol doi: 10.1002/uog.9017 – volume: 357 start-page: 1191 year: 2001 ident: key2019021912542515_ref1-bib19 article-title: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(00)04337-3 – volume: 7 start-page: CD004947 year: 2013 ident: key2019021912542515_ref1-bib6 article-title: Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD004947.pub3 – volume: 12 start-page: 79 year: 2012 ident: key2019021912542515_ref1-bib17 article-title: Trial protocol OPPTIMUM – does progesterone prophylaxis for the prevention of preterm labour improve outcome? publication-title: BMC Pregnancy Childbirth doi: 10.1186/1471-2393-12-79 – volume: 387 start-page: 2106 year: 2016 ident: key2019021912542515_ref1-bib8 article-title: Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00350-0 – volume: 8 start-page: 25 year: 2002 ident: key2019021912542515_ref1-bib14 article-title: Systematic review of chorioamnionitis and cerebral palsy publication-title: Ment Retard Dev Disabil Res Rev doi: 10.1002/mrdd.10003 – volume: 105 start-page: 273 year: 2005 ident: key2019021912542515_ref1-bib23 article-title: Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials publication-title: Obstet Gynecol doi: 10.1097/01.AOG.0000150559.59531.b2 – volume: 8 start-page: 24 year: 1999 ident: key2019021912542515_ref1-bib24 article-title: Ergebnisse der Bayerischen Entwicklungstudie: implikationen fur theorie und praxis publication-title: Kindheit und Entwicklung doi: 10.1026//0942-5403.8.1.23 – volume: 74 start-page: 17 year: 2013 ident: key2019021912542515_ref1-bib5 article-title: Preterm birth-associated neurodevelopmental impairment estimates at regional and global levels for 2010 publication-title: Pediat Res doi: 10.1038/pr.2013.204 – volume: 206 start-page: 124 year: 2012 ident: key2019021912542515_ref1-bib7 article-title: Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2011.12.003 – volume-title: Preterm Labour and Birth year: 2015 ident: key2019021912542515_ref1-bib21 – volume: 188 start-page: 419 year: 2003 ident: key2019021912542515_ref1-bib2 article-title: Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study publication-title: Am J Obstet Gynecol doi: 10.1067/mob.2003.41 – volume: 206 start-page: 376 year: 2012 ident: key2019021912542515_ref1-bib20 article-title: Progesterone and preterm birth prevention: translating clinical trials data into clinical practice publication-title: Am J Obstet Gynaecol doi: 10.1016/j.ajog.2012.03.010 – volume: 112 start-page: 293 year: 2005 ident: key2019021912542515_ref1-bib22 article-title: Fetal fibronectin test predicts delivery before 30 weeks of gestation in high risk women, but increases anxiety publication-title: BJOG doi: 10.1111/j.1471-0528.2004.00420.x |
| SSID | ssj0041651 |
| Score | 2.3577054 |
| Snippet | Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.
To determine the... Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term... Background: Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1 |
| SubjectTerms | Administration, Intravaginal Bronchopulmonary Dysplasia - prevention & control childhood Double-Blind Method Europe Female Fibronectins - blood Gestational Age Humans neonatal Obstetric Labor, Premature - prevention & control Perinatal Death - prevention & control Pregnancy pregnancy prevention Pregnancy Trimester, Third Premature Birth - prevention & control preterm birth Progesterone - administration & dosage progestogens |
| Title | Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29945711 https://www.proquest.com/docview/2060869054 https://pubmed.ncbi.nlm.nih.gov/PMC6036405 https://doaj.org/article/05997d3dc1f440668e89548932e46171 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2046-4924 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041651 issn: 1366-5278 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9tAEF3aUEovpd9xm4YtFNoeRKSV9kOnkqQN7cGpDwn4JnZXs8RgpGJLpb-gv7szK9nYJdBLTkZeCa1mRnpvtKM3jL3HEELeJlziU1ViglLLBFmrS7SoPebMUjjlYrMJfXlp5vNyttPqi2rCBnngwXAnpB-i6xyPDAWCjzJgSKMMaQcUiL4x8UHWs0mmhmcwsgw5fnGlMNXSZpCdzZHLnNx0FiGRvrPfAaKo138byfy3VnIHfC6esMcja-Snw2yfsnvQPGMPp-O6-HP250sLa061VlH4oG2ANtCCS_t7seZdi5tRqol-6WHMyfn9ii_iOwXgbd9h6MFnfsoRvOoWvQ81r9veLSFxSEVrHqu3XJuMxe1LHI8tP_jHH7PZ1ffp9fTTC3Z98fXq_FsydlhIfK7LNHFCq6I2VllhAZGfsgcDNZjgpc5BQCm8UzJ4X2RZQLKBFgxI2JRPjc0Q_16ygwav6ZBxF5zNggvC5RkJwLgSkPxJMKmFvAgwYR825q78KD9OXTCWFaYh5Jhq45gJe7fd8-cguXHLPmfkse04iWTHPzB0qjF0qv-FDp5o4-8KzUorJbaBtl9XIlUpteqSxYS9Gvy_PRXidyF1hkfrvcjYm8v-SLO4icLdihZ9U_n6Lib_hj1C7maGqrUjdtCtenjLHvhf3WK9Omb39dwcx3viLwQLDxM |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Does+progesterone+prophylaxis+to+prevent+preterm+labour+improve+outcome%3F+A+randomised+double-blind+placebo-controlled+trial+%28OPPTIMUM%29&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=Norman%2C+Jane+E&rft.au=Marlow%2C+Neil&rft.au=Messow%2C+Claudia-Martina&rft.au=Shennan%2C+Andrew&rft.date=2018-06-01&rft.eissn=2046-4924&rft.volume=22&rft.issue=35&rft.spage=1&rft_id=info:doi/10.3310%2Fhta22350&rft_id=info%3Apmid%2F29945711&rft.externalDocID=29945711 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1366-5278&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1366-5278&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1366-5278&client=summon |